ASP015K

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bioavailability of ASP015K

Conditions

Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K

Trial Timeline

May 1, 2013 → Aug 1, 2013

NCT ID

NCT01929577

About ASP015K

ASP015K is a phase 1 stage product being developed by Astellas Pharma for Bioavailability of ASP015K. The current trial status is completed. This product is registered under clinical trial identifier NCT01929577. Target conditions include Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02586194	Phase 1	Completed	Dec 28, 2015	Sep 27, 2016	Patients With Impaired Hepatic Function
NCT02603497	Phase 1	Completed	Nov 24, 2015	Dec 19, 2016	Patients With Impaired Renal Function
NCT01929577	Phase 1	Completed	May 1, 2013	Aug 1, 2013	Bioavailability of ASP015K
NCT01484964	Phase 1	Completed	Sep 1, 2011	Oct 1, 2011	Pharmacokinetics of ASP015K
NCT01486017	Phase 1	Completed	Sep 1, 2011	Sep 1, 2011	Bioavailability of ASP015K
NCT01406132	Phase 1	Completed	Dec 1, 2009	Jan 1, 2010	Healthy Subjects

Competing Products

20 competing products in Bioavailability of ASP015K

See all competitors

Product	Company	Stage	Hype Score
solifenacin succinate suspension + solifenacin succinate tablet	Astellas Pharma	Phase 1	33
ASP015K	Astellas Pharma	Phase 1	33
Ipragliflozin	Astellas Pharma	Phase 1	33
Hetrombopag	Jiangsu Hengrui Medicine	Phase 1	33
ABT-450/r/ABT-267	AbbVie	Phase 1	33
ABT-333	AbbVie	Phase 1	33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2	AstraZeneca	Phase 1	33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orally	AstraZeneca	Phase 1	33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single dose	AstraZeneca	Phase 1	33
selumetinib 75mg single dose	AstraZeneca	Phase 1	33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube	AstraZeneca	Phase 1	33
AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423	AstraZeneca	Phase 1	33
Fostamatinib + Fostamatinib + Fostamatinib + Fostamatinib	AstraZeneca	Phase 1	33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcg	AstraZeneca	Phase 1	33
D1400147 + D14000136 + D14000137 + Epanova®	AstraZeneca	Phase 1	33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water	AstraZeneca	Phase 1	33
NKTR-118 + Ketoconazole	AstraZeneca	Phase 1	33
TEPEZZA + EDP	Amgen	Phase 1	32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir	Pfizer	Phase 1	32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332	Pfizer	Phase 1	32

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved